Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Agomelatine monotherapy for major depressive disorder
ChiCTR2200066866Phase 4Completed
- Sponsor
- Beijing Anding Hospital
- Start
- Sep 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of agomelatine in major depressive disorder (MDD), sponsored by Beijing Anding Hospital. Primary endpoint: Change in total HAMD-17 score from baseline. Started Sep 2017; status: completed.
02
Drugs
agomelatine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on ChiCTR2200066866.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200066866.